8-K current report · filed Jul 2, 2026

BridgeBio Pharma, Inc. (BBIO) 8-K Current Report: July 2, 2026

Item 1.01Item EX-99.1Item 3.02Item 3.03Item 7.01Item 5.03BBIO overview

Short answer

BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 3.02 (Unregistered Sales of Equity Securities), Item 3.03 (Material Modification to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). $933.9M preferred equity financing: Sixth Street $800M and HCR $133.9M, strengthening BridgeBio’s capital base.

BridgeBio Pharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $933.9M preferred equity financing: Sixth Street $800M and HCR $133.9M, strengthening BridgeBio’s capital base
  • 7.00% cumulative dividend, payable in cash or compounded, creating significant recurring financing cost
  • Preferred stock converts initially at $137.79 per share, with participation in common-stock dividends and senior liquidation priority
  • Sixth Street affiliates hold an additional $66.1M funding option, subject to Board approval
  • Investor protections include consent rights over senior securities, certain debt and restricted payments, plus potential stockholder approval by June 30, 2027

Item 3.02 · Unregistered Sales of Equity Securities

  • Preferred Stock initially convertible into 6,777,705 common shares, creating potential shareholder dilution
  • Anti-dilution provisions and Certificate of Designations terms could change the eventual conversion share count
  • Unregistered issuance limits immediate market transparency and resale flexibility for purchasers
  • Accredited-investor transaction under Securities Act Sections 4(a)(2) and 3(a)(9) exemptions

Item 3.03 · Material Modification to Rights of Security Holders

  • Preferred Stock issuance subordinates Common Stock to senior dividend and liquidation rights
  • Common Stock holders face reduced recovery priority if BridgeBio liquidates or dissolves
  • Company restrictions on Common Stock dividends, repurchases and redemptions now apply
  • Investor impact depends on Preferred Stock terms in the Certificate of Designations

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Series A preferred stock rights formally established through a Delaware Certificate of Designations
  • Effective immediately upon filing, creating a new preferred equity security class
  • Investor impact depends on conversion, participation, dividend and priority terms in Exhibit 3.1
  • Issuance links to Item 1.01 and Item 3.03, signaling material financing and potential capital-structure changes

Item 7.01 · Regulation FD Disclosure

  • Press release announces the Item 1.01 transactions, making deal terms and strategic rationale market-relevant
  • Exhibit 99.1 contains the substantive transaction details for investor review

Item EX-99.1 · Exhibit EX-99.1

  • $1B preferred-equity financing strengthens liquidity for launches and pipeline investment
  • Sixth Street funded $800M; HealthCare Royalty funded $133.9M at closing
  • 7.00% cumulative dividend, payable in cash or kind, creating material funding cost
  • Initial conversion price $137.79, more than 100% above 30-day VWAP; increases to $153.10 after year five
  • Capital supports potential launches of BBP-418, encaleret, and infigratinib within 12 months

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BridgeBio Pharma, Inc. 8-K filings

Get the next BBIO 8-K as it lands

Follow BBIO for push alerts, or ask the research agent what this filing means.